Contemporary image-guided thermal ablation in oncology integrates clinical evaluation with advanced multimodal imaging to achieve precise, effective, and safe tumor eradication. Procedural success relies on high-resolution imaging to accurately map target lesions, delineate tumor morphology, assess microvascularity, and define spatial relationships to critical structures, ensuring that ablation can be performed with an adequate margin—typically of 0.5–0.7 cm of surrounding parenchyma. The introduction of contrast enhanced ultrasound (CEUS) and second-generation microbubble contrast agents has redefined the role of conventional ultrasound by providing real-time, high-temporal-resolution visualization of tissue perfusion and microvascularity. CEUS retains the inherent advantages of ultrasound–portability, absence of ionizing radiation, and dynamic feedback—while improving lesion detection, characterization, targeting of viable tumor, and post-treatment assessment. Recent advances in imaging-based software further enhance procedural precision through three-dimensional mapping, virtual needle trajectory planning, and ablation zone prediction. The integration data across modalities—via fusion imaging of CEUS, contrast-enhanced CT, and contrast-enhanced MRI—improves accuracy, safety, and longitudinal treatment surveillancetreatment surveillance. Collectively, these innovations position CEUS as an indispensable tool applied across a broad spectrum of locoregional therapies, driving precision across the four key phases of image-guided oncologic therapy: pre-procedural planning, intraprocedural targeting, intraprocedural monitoring and control, and post-procedural assessment.